Jubilant Life Sciences receives ANDA approvals for Valsartan Tablets

From USFDA

Jubilant Life Sciences announced that it has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Valsartan Tablets USP, 40 mg, 80 mg, 160 mg and 320 mg, the generic version of Diovan (of Novartis), used as an anti-hypertensive.

Powered by Capital Market - Live News